Senzagen
  • Home
  • Services
    • At a glance
      • Testing with us
      • Who we work with
      • GLP
    • GARD: Skin and Respiratory Sensitization Testing
      • GARDskin: OECD TG 442E
      • GARDpotency: OECD TGP 4.106
      • GARDskin Medical Device: ISO 10993-10
      • GARDskin Dose-Response
      • GARDair
      • “Difficult-to-test” samples
    • Regulatory Toxicity Testing
      • Skin corrosion: OECD TG 431
      • Skin irritation: OECD TG 439
      • Skin sensitization: OECD TG 442C, 442D, 442E
      • Skin absorption: OECD TG 428
      • Eye irritation: OECD TG 492, 492B
      • Phototoxicity: OECD TG 432, 498
      • Genotoxicity: OECD TG 471, 487
      • Full list of regulatory tests
    • Biological Evaluation of Medical Devices
      • Overview
      • In vitro biocompatibility testing
        • Cytotoxicity: ISO 10993-5
        • Irritation: ISO 10993-23
        • Skin sensitization: ISO 10993-10
      • Substance-based Medical Devices
        • Mode of action
        • Penetration, distribution and absorption
    • Toxicology Advisory
      • Areas of expertise
      • The team
      • Medical Devices
      • Cosmetics
      • Chemicals
      • Pharmaceuticals
  • Science
    • GARD Technology
    • Science Behind
    • Scientific Publications
    • Posters
    • Webinars
  • Company
    • About Us
    • Sustainability
    • Career
    • Partners
  • Investors
    • SenzaGen at a Glance
    • Financial Reports
    • Press Releases
    • The Share
    • Analyst Coverage
    • Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Auditor
      • Nomination Committee
      • Annual General Meeting
    • Calendar
    • Prospekt / Emission
  • News and Events
    • Press Releases
    • News Posts
    • Event Calendar
  • Contact
  • Get a quote
  • Search
  • Menu Menu

SenzaGens delårsrapport januari-juni 2024: Tillväxt med 30 % i Q2 samt säkrad finansiering till nya kommersiella tillväxtprojekt

SenzaGen’s interim report January–June 2024: 30% growth in Q2, and funding secured for new commercial growth projects

SenzaGen has carried out a directed share issue of approximately SEK 37.2 million

SenzaGen har genomfört en riktad emission av aktier motsvarande cirka 37,2 MSEK

SenzaGen avser genomföra en riktad nyemission av aktier

SenzaGen intends to carry out a directed issue of shares

Report from AGM of SenzaGen AB on 15 May 2024

Kommuniké från årsstämma i SenzaGen AB den 15 maj 2024

SenzaGen’s interim report January–March 2024: Breakeven in Q1 2024

SenzaGens delårsrapport januari-mars 2024: Break-even i Q1 2024

Page 1 of 14123›»

Pages

  • Annual General Meeting
  • Auditor
  • ChatTest
  • Get a quote
  • Home
  • License Partners
  • Optionsprogram
  • SenzaGen at a glance
  • SenzaGen at Eurotox 2024
  • Sustainability
  • Thank you for your request
  • Advisory chemicals
  • Advisory cosmetics
  • Advisory medical devices
  • Advisory pharma
  • Area of expertise
  • Cytotoxicity: ISO 10993-5 MTT/MEM Elution Test
  • Full list of regulatory tests
  • GARD Technology
  • GARDair
  • GARDskin: OECD TG 442E
  • In vitro biocompatibility testing
  • In vitro penetration, distribution and absorption
  • Irritation: ISO 10993-23
  • Mode of Action
  • Overview: Biological Evaluation of Medical Devices
  • Skin corrosion: OECD TG 431
  • Skin irritation: OECD TG 439
  • Substance-based Medical Devices
  • The Expert Team
  • Board of directors
  • Press releases
  • Science behind
  • Services
  • Skin sensitization
  • Skin sensitization with GARD: ISO 10993-10
  • The SenzaGen Share
  • Who we work with
  • GARDair_old
  • GARDskin Dose-Response
  • Management
  • News Posts
  • Respiratory sensitization
  • Science
  • Scientific publications
  • About
  • Career
  • Difficult-to-test
  • GARDpotency: OECD TGP 4.106
  • Posters
  • Application notes
  • Event Calendar
  • Financial Reports
  • GLP
  • Investors
  • Partners
  • Corporate Governance
  • News and Events
  • Webinars
  • Calendar
  • Contact
  • Analyst Coverage
  • Presentations
  • Distributors & Contract labs
  • GARDpotency_old
  • GARDskin Dose-Response_old
  • GARDskin Medical Device_old
  • Mixed media
  • Nomination Committee
  • Partner login
  • Posts
  • Prenumerera
  • Prenumerera – fail
  • Prenumerera – success
  • Press releases-mfn
  • Prospekt och Listning NASDAQ First North
  • Regional representatives
  • Scientific advisors
  • Skin potency classification
  • Subscription
  • Test
  • Test
  • test-yearly
  • Testing
  • Testing 2
  • Ticker

Categories

  • Difficult-to-test
  • Distributors
  • Events
  • Financial events
  • Finansiella rapporter
  • GARD technology platform
  • GARDair
  • GARDpotency
  • GARDprotein
  • GARDskin
  • GARDskin Dose-Response
  • GARDskin Medical Device
  • Licence laboratories
  • News/posts
  • Photosensitization
  • Podcast
  • Posters
  • Press releases – English
  • Pressmeddelanden – Svenska
  • Regulatoriska
  • Regulatory
  • Respiratory Sensitization
  • Risk Assessment of Medical Devices
  • Scientific publications
  • Skin Sensitizing Hazard Identification
  • Skin Sensitizing Potency Assessment
  • Uncategorized

Archive

  • October 2024
  • August 2024
  • June 2024
  • April 2024
  • March 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • December 2022
  • November 2022
  • October 2022
  • August 2022
  • July 2022
  • April 2022
  • March 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • December 2020
  • November 2020
  • October 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • September 2019
  • August 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • November 2014
  • August 2014
  • June 2014
  • May 2014
  • April 2014
  • February 2014
  • June 2013
  • April 2013
  • December 2011
  • August 2011
  • February 2006

Quick Links

Contact
Privacy Policy (En)
Privacy Policy (Sv)
General Terms and Conditions

Pages

  • Home
  • Services
  • Investors
  • Contact
  • News and Events

Follow Us

SUBSCRIBE TO PRESS RELEASES

Scroll to top

Subscribe


Prenumerera